98%
921
2 minutes
20
The use of moving bed biofilm reactor (MBBR) systems for the treatment of municipal and industrial wastewater has been shown to gain more attention, in contrast to activated sludge systems. However, little is known about the effects of pharmaceuticals on constituent microbial communities. This study investigated the shift in microbial community compositions of biofilms in an MBBR due to exposure to specific antiretroviral (ARV) compounds. Microbial diversity (alpha-diversity) of seeded sludge from a full-scale municipal wastewater treatment plant and biofilm samples from a laboratory-scale MBBR system during pre- and post-introduction of ARV compounds was investigated by Illumina sequencing of the 16S rRNA gene. Microbial diversity results demonstrated that the introduction of ARV drugs affects the bacterial community composition and diversity considerably. For instance, the genus , , and was found to be higher in post-introduction of ARV compounds biofilm samples than in biofilm samples before the introduction of ARV compounds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2166/wst.2025.121 | DOI Listing |
Exp Biol Med (Maywood)
August 2025
Division of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States.
The antiretroviral (ARV) drug combination of abacavir sulfate, dolutegravir, and lamivudine [ABC/DTG/3TC; Tri combination Anti-retroviral therapy (TC-ART)] has revolutionized HIV treatment by effectively targeting different stages of viral replication. Despite its therapeutic efficiency for maintaining low viremia in the mother during pregnancy, there are concerns for long-term liabilities in offspring that are indirectly exposed during vulnerable periods of development. The commensal microbiota plays a crucial role in maintaining overall gut health, and disruption of the microbiome is often linked to various extraintestinal effects such as immune dysregulation and inflammation.
View Article and Find Full Text PDFWater Sci Technol
August 2025
Department of Natural Sciences, Vaal University of Technology, Vanderbijlpark Campus, Vanderbijlpark 1911, South Africa E-mail:
The use of moving bed biofilm reactor (MBBR) systems for the treatment of municipal and industrial wastewater has been shown to gain more attention, in contrast to activated sludge systems. However, little is known about the effects of pharmaceuticals on constituent microbial communities. This study investigated the shift in microbial community compositions of biofilms in an MBBR due to exposure to specific antiretroviral (ARV) compounds.
View Article and Find Full Text PDFJ Med Chem
August 2025
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Urology of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Proteolysis-targeting chimeras (PROTACs) are an emerging class of therapeutic agents for anticancer treatments by degrading intracellular proteins via the ubiquitin-proteasome system. However, clinical applications of PROTACs are limited by the undesired normal cell toxicity resulting from off-tissue on-target degradation. To address this, we developed a tumor-selective delivery strategy by conjugating carbohydrate moieties to the ligand of the VHL E3 ubiquitin ligase, which enables targeted degradation of proteins of interest in GLUTs-overexpressing cancer cells.
View Article and Find Full Text PDFJ Labelled Comp Radiopharm
July 2025
Science & Technology Innovation Center, Zhejiang Isotope Technologies Co., Ltd, Hangzhou, Zhejiang Province, China.
N-((1R,4R)-4-(3-Chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide (ARV-110) is a proteolysis-targeting chimera (PROTAC) designed against the androgen receptor (AR), which shows great potential for treating AR-dependent diseases, such as prostate cancer. To support preclinical safety evaluations as well as studies of drug metabolism and pharmacokinetics, two versions of carbon-14-labeled ARV-110 were synthesized: N-((1R,4R)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-[1,3-C2]dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide (C-ARV-110-a) and N-((1R,4R)-4-(3-chloro-4-[cyano-C]cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide (C-ARV-110-b). The synthesis of C-ARV-110-a was initiated from 1,2-dibromo-4,5-difluorobenzene and zinc cyanide-C (Zn(CN)₂), while C-ARV-110-b was prepared from 2-chloro-4-fluoro[cyano-C]benzonitrile.
View Article and Find Full Text PDFInt J Mol Sci
June 2025
Philips Institute for Oral Health Research, School of Dentistry, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Head and neck squamous cell carcinoma (HNSCC) remains challenging to treat despite multimodal therapeutic approaches. Cisplatin treatment is effective and cost-efficient, although chemoresistance and disease recurrence limit its efficacy. Understanding the mechanisms of cisplatin resistance and the identification of compounds to target resistant tumor cells are critical for improving patient outcomes.
View Article and Find Full Text PDF